T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein Journal Article
| Authors: | Uenaka, A.; Wada, H.; Isobe, M.; Saika, T.; Tsuji, K.; Sato, E.; Sato, S.; Noguchi, Y.; Kawabata, R.; Yasuda, T.; Doki, Y.; Kumon, H.; Iwatsuki, K.; Shiku, H.; Monden, M.; Jungbluth, A. A.; Ritter, G.; Murphy, R.; Hoffman, E.; Old, L. J.; Nakayama, E. |
| Article Title: | T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein |
| Abstract: | We recently showed that vaccination with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein (CHP-NY-ESO-1) elicited antibody responses in 9 of 9 patients vaccinated in a clinical trial. In this study, we performed T cell immunomonitoring and analyzed tumor responses in these patients. To evaluate CD4 and CD8 T cell responses, an IFN-γ secretion assay was used. The assay showed low background and was sensitive for detecting antigen-specific T cells. An increase in the CD4 T cell response was observed in 2 of 2 initially sero-positive and 5 of 7 initially sero-negative patients after vaccination. An increase in the CD8 T cell response was also observed in 2 of 2 sero-positive and 5 of 7 sero-negative patients after vaccination. Analysis of peptides recognized by CD4 and CD8 T cells revealed two dominant NY-ESO-1 regions, 73-114 and 121-144. Tumor responses were observed in 3 esophageal cancer patients and a malignant melanoma patient. In 3 of 4 prostate cancer patients, prostate-specific antigen (PSA) values stabilized during the course of vaccination. The use of whole protein, containing multiple CD4 and CD8 epitopes, may be beneficial for cancer vaccines to prevent tumors from evading the immune response. Copyright © 2007 by Eiichi Nakayama. |
| Keywords: | immunohistochemistry; adult; clinical article; controlled study; aged; unclassified drug; clinical trial; cd8+ t lymphocyte; t lymphocyte; prostate specific antigen; melanoma; controlled clinical trial; prostate cancer; pruritus; cellular immunity; immune response; gamma interferon; cancer vaccine; antigen specificity; ny eso 1 antigen; cancer immunization; cd4+ t lymphocyte; erythema; tumor immunity; tumor; tumor vaccine; transurethral resection; esophagus cancer; immunochemistry; blister; chp-ny-eso-1; cholesterol bearing hydrophobized pullulan |
| Journal Title: | Cancer Immunity |
| Volume: | 7 |
| ISSN: | 1424-9634 |
| Publisher: | Academy of Cancer Immunology |
| Date Published: | 2007-04-19 |
| Start Page: | 9 |
| Language: | English |
| PROVIDER: | scopus |
| PMCID: | PMC2935756 |
| PUBMED: | 17441676 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 14" - "Export Date: 17 November 2011" - "Source: Scopus" |
Citation Impact
Related MSK Work